Bristol-Myers Squibb Long Term Debt

Bristol-Myers Squibb posts a long-term debt of $42B as of June 2026. That compares with $-44B in the prior-year period — up 194.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Bristol-Myers Squibb's long-term debt was $-44B. The latest reading is $42B — a 194.7% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of Bristol-Myers Squibb's financial statement story. At $42B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BMY's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Bristol-Myers Squibb's other metric pages and overview cover the third.

Judging Bristol-Myers Squibb against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $42B here, then scan peer and history charts to see if the gap is persistent.